SG Americas Securities LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

SG Americas Securities LLC acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 28,631 shares of the company's stock, valued at approximately $773,000.

Other large investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in shares of Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after purchasing an additional 599 shares during the period. New York State Common Retirement Fund increased its position in shares of Janux Therapeutics by 84.6% in the fourth quarter. New York State Common Retirement Fund now owns 15,964 shares of the company's stock worth $855,000 after purchasing an additional 7,318 shares during the period. Handelsbanken Fonder AB bought a new position in shares of Janux Therapeutics in the fourth quarter worth $642,000. HealthInvest Partners AB bought a new position in shares of Janux Therapeutics in the fourth quarter worth $2,078,000. Finally, Proficio Capital Partners LLC bought a new position in shares of Janux Therapeutics in the fourth quarter worth $1,353,000. Institutional investors own 75.39% of the company's stock.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the sale, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,464,170. This trade represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on JANX shares. Scotiabank decreased their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. Wedbush restated an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Stock Down 0.8%

NASDAQ:JANX opened at $22.72 on Friday. The stock's 50-day simple moving average is $26.77 and its 200 day simple moving average is $36.44. The firm has a market capitalization of $1.34 billion, a PE ratio of -16.71 and a beta of 2.96. Janux Therapeutics, Inc. has a twelve month low of $22.48 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 9.29% and a negative net margin of 463.91%. On average, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.